



PSORIASIS

DRUG SURVIVAL OF USTEKINUMAB IN 8 YEARS OF USE AT THE DERMATOLOGY UNIT OF UNIVERSITY OF CAMPANIA “LUIGI VANVITELLI”

F Romano⁽¹⁾ - A Lo Schiavo⁽²⁾

University Of Campania “luigi Vanvitelli”, Dermatology Unit, Naples, Italy⁽¹⁾ - University Of Campania “luigi Vanvitelli”, Università Degli Studi Della Campania “luigi Vanvitelli”, Naples, Italy⁽²⁾

INTRODUCTION: Drug survival is an indicator for treatment sustainability in chronic diseases such as psoriasis.

OBJECTIVE: The aim of these analyses was to assess survival of ustekinumab in eight years of use at the Dermatology Unit of University of Campania “Luigi Vanvitelli”.

MATERIALS AND METHODS: The definition of drug survival goes from initiation to discontinuation (stop/switch) of biologic therapy. The number of patients who discontinued each treatment and the duration of therapy were recorded using Kaplan-Meier survival curves.

RESULTS: Since year 2010, 450 patients initiated a new biologic therapy, 196 of them started ustekinumab. Lack of effectiveness was the most common reason for discontinuation therapies.

CONCLUSION: In our experience, ustekinumab has shown the high drug survival in biologic patients, as this data demonstrate the efficacy and safety of anti IL12-23 in psoriasis patients.

